Latest news

Debiopharm mutualise son infrastructure de bornes de recharges pour les taxis électriques ou hybrides de Lausanne

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…

Lancement de la 10e édition du Challenge Qualité de Vie du Patient

Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways

Debiopharm Innovation Fund welcomes Hope AI to their portfolio

Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea

Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles